title: [Factors that influence the duration of peripheral venous catheters used to antibiotic therapy in Cystic Fibrosis patients: results of a study].
abstract: Antibiotic intravenous (IV) therapy is of paramount importance in the treatment of cystic fibrosis (CF) lung disease. During their life CF patients have to undergo frequent IV antibiotic treatments. Peripheral venous catheters (PVC) -or cannulas- are often used to reduce the number of venepunctures needed to complete a treatment cycle, as well as to provide patients the best possible level of autonomy. The clinical experience in managing IV therapy in CF patients at Meyer Hospital in Florence, suggested that the in situ duration of PVCs varies greatly.
  
  
  OBJECTIVE
  To understand which factors influence the duration of PVCs used to administer IVantibiotic in people with CF.
  
  
  METHODS
  Cohort prospective study, integrated with retrospective data retrieval. MATERIALS, PATIENTS AND METHODS: We observed all the PVCs inserted during an 8-month period to CF patients followed at the CF Centre of Tuscany (Florence, Italy).
  
  
  RESULTS
  We studied 87 PVCs inserted to 36 patients in 56 IV antibiotic treatment cycles. The mean duration of PVCs was 8.3 days. The mean duration of PVCs used for 3 daily antibiotic administrations was longer than that of PVCs used for 2 daily antibiotic administrations (10.3 days vs. 6.5 days, p=0.001). Moreover, PVCs with a larger gauge (G22) had longer mean duration than smaller (G24) PVCs (9.6 days vs. 7.2 days, p=0.03). No statistically significant association was found between PVCs' duration and, respectively, the place where the treatment was administered (in hospital or at home), the arm used (dominant or non-dominant), the PVC's brand, patient's clinical condition and the concurrent use of either steroidal antinflammatory drugs or NSAIDs per os.
authors.affiliation: Nucleo Operativo per la Ri- cerca Infermieristica, Azienda Ospedaliero-Universitaria Meyer, via L.Giordono 13, 50132 Firenze.
authors.forename: Filippo
authors.initials: F
authors.lastname: Festini
authors.forename: Raffaella
authors.initials: R
authors.lastname: Beneventi
authors.forename: Noemi
authors.initials: N
authors.lastname: Vignoli
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Allegretti
authors.forename: Isabella
authors.initials: I
authors.lastname: Rontini
authors.forename: Elena
authors.initials: E
authors.lastname: Campigatto
authors.forename: Gilda
authors.initials: G
authors.lastname: Grondoni
authors.forename: Silvia
authors.initials: S
authors.lastname: Sanasi
authors.forename: Gianna
authors.initials: G
authors.lastname: Bongini
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D002406:Catheterization, Peripheral; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003550:Cystic Fibrosis / Q000188:drug therapy*; D005260:Female; D006699:Home Care Services; D006801:Humans; D007297:Inpatients; D008297:Male; D011446:Prospective Studies; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal